Navigation Links
Medtronic, Lilly Diabetes Join Together as First Ever National Presenting Sponsors of the JDRF Walk To Cure Diabetes
Date:11/1/2013

e is a cure. Thanks to Walks and other fundraising efforts, JDRF has become the world's leading funder of T1D research, and is a powerful advocate for the T1D community.

This is the first co-sponsorship for the Medtronic-Lilly Alliance and the first time JDRF will have a national presenting Walk sponsor. The Medtronic-Lilly Alliance was established in 2009 to combine the insulin expertise of Lilly with the advanced diabetes technologies of Medtronic.

"At Medtronic, everything we do is focused on the goal of improving the lives of people with diabetes," said Nancy Katz, vice president of consumer marketing for the diabetes business unit at Medtronic. "The JDRF Walks have long been a big part of our tradition of community involvement, allowing our team to support and connect with people with diabetes all across the country. By sponsoring the JDRF Walk to Cure Diabetes with Lilly Diabetes, we're thrilled to be working with two organizations that share our dedication to diabetes education and community support."

More than 200 JDRF Walks are held every year in the United States and around the world. Participants, walking alone or in teams, as well as virtual walkers and other volunteers, work together to raise money for JDRF. The program's national sponsors play a large role in supporting all JDRF Walk to Cure Diabetes events throughout the country.

"Sponsoring the JDRF Walk to Cure Diabetes is an important milestone in Lilly's partnership with Medtronic and means a lot to our employees," said Mike Mason, vice president, US, Lilly Diabetes. "Every day we strive to support people living with diabetes in their journeys with the disease. Sponsoring the JDRF Walk to Cure Diabetes will provide support the day of the walk and for years to come by helping JDRF further its important work in diabetes research and advocacy."

2014 Walks begin around the country on
'/>"/>

SOURCE Eli Lilly and Company; Medtronic
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Zacks.com featured expert Kevin Matras highlights: Core Laboratories NV, Invesco Ltd., Medtronic, Inc., Willbros Group Inc. and WuXi PharmaTech Inc.
2. Buoyed by Forecasts, Where 2013 Leads - Research Report on ResMed Inc., Zimmer Holdings, Inc., Waters Corporation, Covidien PLC, and Medtronic, Inc.
3. Lilly announces Tapiero retiring; Zulueta promoted to senior vice president and president of Emerging Markets
4. Lilly Reports Third-Quarter 2013 Results
5. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
6. Lilly Declares Fourth-Quarter 2013 Dividend
7. Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year
8. Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013
9. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
10. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
11. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015 A lot of discussion in the ... treating  certain illnesses, injuries, or conditions. As medical science advances, ... methods with ones that they consider to be more cutting ... not one textbook method of treatment that stands out as ...
(Date:1/23/2015)... Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) released ... care leaders and a new study analyzing the impact of increased ... a nationwide coalition working to educate policy makers and the public ... Capitol was focused on how the Iowa ...
(Date:1/23/2015)... , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... personalized immune therapies for operable and inoperable solid tumor cancers, ... at the 7 th Annual Phacilitate Immunotherapy Forum in ... presentation at Phacilitate will take place on January 26 at ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3
... Fifth International Phase III ACTEMRA Study Meets its Primary ... today announced that two-year data from the LITHE (Toci ... Prevention of Structural Joint Damage) study demonstrated ... structural damage to joints in patients with rheumatoid arthritis ...
... Shire plc (LSE: SHP, Nasdaq: SHPGY ), the ... that coadministration of the ADHD medication VYVANSE(R) (lisdexamfetamine dimesylate) CII ... (20 mg X 2), did not alter the median time ... to be reached in the subjects evaluated. In the ...
Cached Medicine Technology:Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients 2Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients 3Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients 4Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients 5Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8
(Date:1/22/2015)... (PRWEB) January 22, 2015 Juvent Sports ... at the 2015 PGA Merchandise Show to bestow a ... incredible female amateur golfer, Arlene McKitrick. The award commemorated ... amateur golf tournament win. She won her first amateur ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... Plainsboro, NJ (PRWEB) January 22, 2015 ... advocate and keynote speaker at the upcoming 32nd ... by ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , ... breast would have gone undetected if she had not ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
Breaking Medicine News(10 mins):Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... for Dental Research (AADR) is presenting an honorary membership ... at the AADR/Research!America Advocacy Day, March 2, 2010, in ... his commitment to the National Institutes of Health (NIH) ... (NIDCR). He remains one of the Senate,s most staunch ...
... that reward workers for meeting certain performance measures for ... use a variety of methods to reward physicians financially ... A new study in the Journal for ... be effective in incentivizing low performing physicians. The article ...
... aimed at helping with planning efforts for a public ... the Harvard School of Public Health (HSPH) have found ... significant anthrax attack in their city or town, most ... obtain prophylactic antibiotics. However, a significant minority of those ...
... ... was featured in a national study of high performance services firms entitled “The High Growth ... , ... 2010 -- Webmarketing 123, a San Francisco Bay Area based search engine marketing firm, was ...
... suggests , FRIDAY, Feb. 19 (HealthDay News) -- In the ... identified a defective signaling pathway that contributes to the severity ... sticky mucus to build up in the lungs and digestive ... genetic diseases in children and young adults. , In the ...
... HRT use explain the trend, researchers say , FRIDAY, ... declining, especially among women over 50 who have estrogen ... the reason why. , After analyzing data on more ... that the decline may be linked with decreasing use ...
Cached Medicine News:Health News:AADR presents honorary membership to Senator Tom Harkin 2Health News:Poll: Hypothetical anthrax attack and antibiotics 2Health News:Poll: Hypothetical anthrax attack and antibiotics 3Health News:Poll: Hypothetical anthrax attack and antibiotics 4Health News:Poll: Hypothetical anthrax attack and antibiotics 5Health News:Poll: Hypothetical anthrax attack and antibiotics 6Health News:Webmarketing 123 Profiled in National Study of High Growth Professional Services Firms 2Health News:Webmarketing 123 Profiled in National Study of High Growth Professional Services Firms 3Health News:Drug Improved Survival in Mice With Cystic Fibrosis 2Health News:Dips in Breast Cancer Rates Seen Most in Affluent Women 2Health News:Dips in Breast Cancer Rates Seen Most in Affluent Women 3
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Testing for Strabismus (ocular misalignment) just became easier. By simply placing the StrabismoScope over the patient's eye, the examiner is able to observe the occluded eye directly, but the patien...
The Welch Allyn 125 BIO is designed to achieve precise binocular viewing and stereopsis easier than ever before. Its observation paths can be adjusted from 48 mm to 74 mm to handle the widest and nar...
Patented coaxial optics, Halogen HPX illumination, and 68 focusing lenses combine for premium quality....
Medicine Products: